Development of operationalized intravenous to oral antibiotic switch criteria

Abstract

These operationalized criteria can be used in daily clinical practice. Future use of these criteria in audits and as rules in clinical decision support systems will facilitate the performance and evaluation of iv-oral switch programmes.

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing

“…Taken together, there might be an emerging trend of lower bioavailability during acute phases of malaria illness for the longer-acting compound in ACT treatments, warranting further investigation. A similar parallel has been noted with antibiotic use in patients with sepsis ( 34 ).…”

Oral Antibiotic Transition in Patients with Bacteremia with a Urinary Source Due to Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli </i>

“…The first episode of monomicrobial bacteremia due to ESBL-producing E. coli (1) derived from the urinary tract in nonneutropenic adult patients (≥ 18 years old) was identified according to previously described criteria (2). Patients who fulfilled the following criteria for intravenous-to-oral transition were included: stable systolic blood pressure, defervescence, controlled source of infection, availability of an active oral antibiotic with in vitro activity, and food consumption or use of other enteral drugs (3). The clinical outcomes in the two treatment groups were compared.…”

Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study

“…Unfortunately, first-line anti-TB drugs are not available intravenously in many of the high TB burden countries, including Brazil. Oral administration of TB drugs is not recommended for patients in ICU [ 5 , 12 ], so in the absence of other therapeutic options, the crushing and nasogastric tube administration of fixed-dose combination (FDC) tablets (rifampin, isoniazid, pyrazinamide and ethambutol) is used. Despite the successful use of FDC tablets in outpatients [ 13 ], it limits the opportunity to tailor doses in special cases, including ICU patients, patients with kidney injury, obese patients or those whose recovery is not progressing as expected.…”